II-17 Peter Bloomingdale
An Artificial Intelligence Framework for Optimal Drug Design
Wednesday 15:35-17:00 |
II-20 Thomas Bouillon
Comparison and selection of dosing regimens by discretization, optimizing efficacy and evaluating exposure demonstrated for KAE609 (Cipargamin)
Wednesday 15:35-17:00 |
II-24 Simona Catozzi
Inter-species and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin
Wednesday 15:35-17:00 |
II-32 Jared Cui
Incorporating complex drug PK with multiple binding targets into a QSP model to predict combined PD effects
Wednesday 15:35-17:00 |
II-55 Janice Goh
A translational toolkit to predict clinical Phase IIb/III outcomes from preclinical mouse studies
Wednesday 15:35-17:00 |
II-59 Sofia Guzzetti
An integrated modelling approach for targeted degradation: insights on optimisation, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions
Wednesday 15:35-17:00 |
II-60 Chihiro Hasegawa
Exploring simplification of a target-mediated drug disposition (TMDD) model for bispecific antibodies for potential application to data-driven modelling
Wednesday 15:35-17:00 |
II-66 Vijay Ivaturi
Novel convolution-based In vitro-In vivo correlation (IVIVC) model with time scaling and bioavailability sub-models for, JORNAY PM®, a methylphenidate hydrochloride delayed-release and extended-release capsule
Wednesday 15:35-17:00 |
II-70 Woojin Jung
Fractal kinetic implementation in population modeling
Wednesday 15:35-17:00 |
II-77 Niklas Korsbo
DeepPumas for automatic discovery of individualizable functions governing longitudinal patient outcomes
Wednesday 15:35-17:00 |
II-78 Anis Krache
Modelling selective cell targeting through avidity to inform bispecific antibody discovery and development
Wednesday 15:35-17:00 |
II-80 Jialin Mao
Shared Learning from a Physiologically-Based Pharmacokinetic Modeling Strategy for Human Pharmacokinetics Prediction through Retrospective Analysis of Genentech Compounds
Wednesday 15:35-17:00 |
II-81 Francois Mercier
Bridging the gap between two-stage and joint models: The case of tumor growth inhibition and overall survival models
Wednesday 15:35-17:00 |
IV-12 Raphaela Gessele
How to inform a QSP model with gene expression data – exemplified with a model on intestinal epithelial integrity and RIPK2 inhibition
Thursday 15:25-16:55 |
IV-39 Sebastian Micluța-Câmpeanu
Automatic model discovery in Quantitative Systems Biology
Thursday 15:25-16:55 |
IV-56 Morgane PHILIPP
Impact of covariate model selection methods on covariate effects and their uncertainty in population pharmacokinetic analysis
Thursday 15:25-16:55 |
IV-59 Fatiha Rachedi
Predicting Motor function scores using uHex4 biomarker effect in Pompe disease
Thursday 15:25-16:55 |
IV-60 Christopher Rackauckas
Robust Parameter Estimation of Rational Ordinary Differential Equations for NLME and QSP
Thursday 15:25-16:55 |
IV-61 Christopher Rackauckas
Uncertainty quantified discovery of chemical reaction systems via Bayesian scientific machine learning
Thursday 15:25-16:55 |
IV-67 Soroush Safaei
Developing a PBPK/PD/Tox Modelling Framework for NANOBODY® Drug Conjugates
Thursday 15:25-16:55 |
IV-74 Sebastiaan Sassen
The importance of model selection for a priori model informed precision dosing of vancomycin
Thursday 15:25-16:55 |
IV-78 Marie Steinacker
Non-linear autoregressive exogenous modelling to predict individual haematotoxicity during chemotherapy
Thursday 15:25-16:55 |
IV-94 Daichi Yamaguchi
Population pharmacokinetic modelling for vancomycin using Bayesian model averaging approach
Thursday 15:25-16:55 |
